FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387602122> ?p ?o ?g. }

• W4387602122 abstract "<p>Figure S1. (A) Representative MRI images for radiographic evaluation of neoadjuvant toripalimab. (B) Representative hematoxylin and eosin staining for histopathological evaluation of neoadjuvant toripalimab. CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease. A modifier “p” refers to pathologic staging after cystectomy. Figure S2. (A) Stacked bar plot shows the percentage of patients with negative or positive PD-L1, low or high TMB, and negative or positive TLS. (B) Oncoprint chart for the mutational landscape of tDNA in patients with ypCR or non-ypCR. Samples were analyzed by whole exome sequencing, and the mutation frequencies of each gene are shown on the right. (C) The line plot illustrates tumor size changes measured by MRI imaging before and after neoadjuvant toripalimab. PD-L1 = programmed death ligand 1; TMB = tumor mutation burden; TLS = tertiary lymphoid structure; ypCR = pathological complete response; pre-tx = pre-treatment; post-tx = post-treatment; MRI = magnetic resonance imaging. Figure S3. (A) Oncoprint chart for the mutational landscape of tDNA and utDNA. Samples were analyzed by whole exome sequencing, and the mutation frequencies of each gene are shown on the right. (B) TMB correlation between tDNA and utDNA as assessed by whole exome sequencing. Red shading indicates 95% confidence interval. Spearman correlation coefficient (r) and P value are shown. tDNA = tumor DNA; utDNA = urinary tumor DNA; TMB = tumor mutation burden. Figure S4. (A) Box plot compares TFsm in utDNA versus ctDNA samples collected at baseline. (B) Venn plots show the number of shared and unique variants in matched utDNA and ctDNA samples. (C) Box plot compares TFcn in utDNA versus ctDNA samples at baseline. (D) Copy number gain (red) and loss (blue) of utDNA and ctDNA, as identified by GISTIC2.0. TFsm = tumor fraction estimate based on somatic mutations; utDNA = urinary tumor DNA; ctDNA = circulating tumor DNA; TFcn = tumor fraction estimate based on copy numbers. Figure S5. (A) The line plot illustrates TFsm changes in utDNA samples upon neoadjuvant toripalimab. (B) The line plot illustrates TFcn changes in utDNA samples before and after neoadjuvant toripalimab. (C) Stacked bar plot showed the percentage of patients with low or high pre-treatment TFsm, TFcn, and MRI measurements according to the optimal cutoff points defined by ROC analysis. (D) Stacked bar plot showed the percentage of patients with low or high post-treatment TFsm, TFcn, and MRI measurements according to the optimal cutoff points defined by ROC analysis. (E) Waterfall plot for the best change of target lesions in 20 patients. The post-treatment urinary MRD status of each patient are arranged along the x-axis. Bar color indicates the pathologic outcome of neoadjuvant toripalimab. TFsm = tumor fraction estimate based on somatic mutations; TFcn = tumor fraction estimate based on copy numbers; MRI = magnetic resonance imaging; utDNA = urinary tumor DNA; utDNA-pre = pre-treatment utDNA; utDNA-post =post-treatment utDNA; ypCR = pathological complete response; pre-tx = pre-treatment; post-tx = post-treatment; MRD = minimal residual disease. Figure S6. (A) Spider plot indicating dynamic changes of TFsm, TFcn, and MRI measurements for each patient during neoadjuvant toripalimab. (B) Box plot illustrates utDNA reduction (defined by TFsm + TFcn < 10%) in utDNA-pre versus utDNA-post samples. (C) IGV plot showing the FGFR3 S249C mutation in patient RZ12 detected by MRD panel sequencing or whole exome sequencing. (D) VAF changes of the FGFR3 S249C mutation in patient RZ12 with progressive disease. TFsm = tumor fraction estimate based on somatic mutations; TFcn = tumor fraction estimate based on copy numbers; MRI = magnetic resonance imaging; C1 = cycle 1; C2 = cycle 2; C3 = cycle 3; C4 = cycle 4; RC = radical cystectomy; ypCR = pathological complete response; MRD = minimal residual disease; WES = whole exome sequencing; tDNA = tumor DNA; utDNA = urinary tumor DNA; utDNA-pre = pretreatment utDNA; utDNA-post = post-treatment utDNA; C2D1 = cycle 2 day 1; VAF = variant allele frequency; PD = progressive disease.</p>" @default.
• W4387602122 created "2023-10-14" @default.
• W4387602122 creator A5002019581 @default.
• W4387602122 creator A5017571148 @default.
• W4387602122 creator A5020602841 @default.
• W4387602122 creator A5027185368 @default.
• W4387602122 creator A5027535273 @default.
• W4387602122 creator A5032529616 @default.
• W4387602122 creator A5033055638 @default.
• W4387602122 creator A5034213895 @default.
• W4387602122 creator A5035234845 @default.
• W4387602122 creator A5041339469 @default.
• W4387602122 creator A5059666944 @default.
• W4387602122 creator A5068729600 @default.
• W4387602122 creator A5074051679 @default.
• W4387602122 creator A5075682354 @default.
• W4387602122 creator A5082959448 @default.
• W4387602122 date "2023-10-13" @default.
• W4387602122 modified "2023-10-15" @default.
• W4387602122 title "Figure S1-S6 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer" @default.
• W4387602122 doi "https://doi.org/10.1158/1078-0432.24304956" @default.
• W4387602122 hasPublicationYear "2023" @default.
• W4387602122 type Work @default.
• W4387602122 citedByCount "0" @default.
• W4387602122 crossrefType "posted-content" @default.
• W4387602122 hasAuthorship W4387602122A5002019581 @default.
• W4387602122 hasAuthorship W4387602122A5017571148 @default.
• W4387602122 hasAuthorship W4387602122A5020602841 @default.
• W4387602122 hasAuthorship W4387602122A5027185368 @default.
• W4387602122 hasAuthorship W4387602122A5027535273 @default.
• W4387602122 hasAuthorship W4387602122A5032529616 @default.
• W4387602122 hasAuthorship W4387602122A5033055638 @default.
• W4387602122 hasAuthorship W4387602122A5034213895 @default.
• W4387602122 hasAuthorship W4387602122A5035234845 @default.
• W4387602122 hasAuthorship W4387602122A5041339469 @default.
• W4387602122 hasAuthorship W4387602122A5059666944 @default.
• W4387602122 hasAuthorship W4387602122A5068729600 @default.
• W4387602122 hasAuthorship W4387602122A5074051679 @default.
• W4387602122 hasAuthorship W4387602122A5075682354 @default.
• W4387602122 hasAuthorship W4387602122A5082959448 @default.
• W4387602122 hasBestOaLocation W43876021221 @default.
• W4387602122 hasConcept C104317684 @default.
• W4387602122 hasConcept C121608353 @default.
• W4387602122 hasConcept C126322002 @default.
• W4387602122 hasConcept C126838900 @default.
• W4387602122 hasConcept C142724271 @default.
• W4387602122 hasConcept C143409427 @default.
• W4387602122 hasConcept C143998085 @default.
• W4387602122 hasConcept C16671776 @default.
• W4387602122 hasConcept C2777701055 @default.
• W4387602122 hasConcept C2780352672 @default.
• W4387602122 hasConcept C501734568 @default.
• W4387602122 hasConcept C502942594 @default.
• W4387602122 hasConcept C54355233 @default.
• W4387602122 hasConcept C71924100 @default.
• W4387602122 hasConcept C86803240 @default.
• W4387602122 hasConceptScore W4387602122C104317684 @default.
• W4387602122 hasConceptScore W4387602122C121608353 @default.
• W4387602122 hasConceptScore W4387602122C126322002 @default.
• W4387602122 hasConceptScore W4387602122C126838900 @default.
• W4387602122 hasConceptScore W4387602122C142724271 @default.
• W4387602122 hasConceptScore W4387602122C143409427 @default.
• W4387602122 hasConceptScore W4387602122C143998085 @default.
• W4387602122 hasConceptScore W4387602122C16671776 @default.
• W4387602122 hasConceptScore W4387602122C2777701055 @default.
• W4387602122 hasConceptScore W4387602122C2780352672 @default.
• W4387602122 hasConceptScore W4387602122C501734568 @default.
• W4387602122 hasConceptScore W4387602122C502942594 @default.
• W4387602122 hasConceptScore W4387602122C54355233 @default.
• W4387602122 hasConceptScore W4387602122C71924100 @default.
• W4387602122 hasConceptScore W4387602122C86803240 @default.
• W4387602122 hasLocation W43876021221 @default.
• W4387602122 hasOpenAccess W4387602122 @default.
• W4387602122 hasPrimaryLocation W43876021221 @default.
• W4387602122 hasRelatedWork W2002934375 @default.
• W4387602122 hasRelatedWork W2006468016 @default.
• W4387602122 hasRelatedWork W2160411124 @default.
• W4387602122 hasRelatedWork W2257755506 @default.
• W4387602122 hasRelatedWork W2261933510 @default.
• W4387602122 hasRelatedWork W2462603952 @default.
• W4387602122 hasRelatedWork W2898558914 @default.
• W4387602122 hasRelatedWork W3127976301 @default.
• W4387602122 hasRelatedWork W4237262135 @default.
• W4387602122 hasRelatedWork W3021493803 @default.
• W4387602122 isParatext "false" @default.
• W4387602122 isRetracted "false" @default.
• W4387602122 workType "article" @default.